ERBB2 and breast carcinoma: Two recent randomized trials demonstrated that in these patients adding additional treatment after surgery - in case of TNBC capecitabine and in case of HER2-positive breast cancer TDM-1 - improved disease-free survival (DFS) and/or overall survival6,7.